Day: August 5, 2021

OMAHA, Neb., Aug. 05, 2021 (GLOBE NEWSWIRE) — On August 5, 2021, America First Multifamily Investors, L.P. (NASDAQ: ATAX) (the “Partnership” or “ATAX”) announced financial results for the three and six months ended June 30, 2021. Financial Highlights As of and for the three months ended June 30, 2021:Total revenues of $16.4 million Net income, basic and diluted, of $0.13 per Beneficial Unit Certificate (“BUC”) Cash Available for Distribution (“CAD”) of $0.17 per BUC Total assets of $1.2 billion Total Mortgage Revenue Bond (“MRB”) and Governmental Issuer Loan (“GIL”) investments of $908.4 millionFor the six months ended June 30, 2021:Total revenues of approximately $30.8 million Net income, basic and diluted, of $0.22 per BUC Cash Available for Distribution of $0.28 per BUCThe Partnership reported the following notable transactions...

PHILADELPHIA and MIAMI, Aug. 05, 2021 (GLOBE NEWSWIRE) — Hill International (NYSE:HIL), delivering the infrastructure of change, announced today it was awarded a contract to provide program management services for the Miami-Dade County Aviation Department’s (MDAD) $5 billion Capital Improvement Program (CIP). The program encompasses Miami International Airport as well as all the County’s executive and general aviation airports and will support modernization projects over the next 15 years. These improvements will accommodate dramatic growth at MDAD’s airports, with total passengers expected to reach 60 million annually over the life of the program. Due to MIA being the first IATA-Designated Pharma Hub Airport in the U.S. and substantial growth in e-commerce, freight traffic is also expected to increase substantially to a total...

LA JOLLA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) —  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that Raymond J. Tesi, MD, President and CEO, will present at the BTIG Virtual Biotechnology Conference being held August 9 – 10. BTIG Virtual Biotechnology ConferencePresentation Date: Monday, August 9, 2021Presentation Time: 1:00 PM Eastern TimeInformation:  Click Here Please contact your representative at BTIG to schedule a virtual one-on-one meeting with INmune Bio during the respective conference. About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system...

COLLINGWOOD, Ontario, Aug. 05, 2021 (GLOBE NEWSWIRE) — The Limestone Boat Company Limited (“Limestone”) (TSXV:BOAT) – owner and builder of Aquasport Boats, Limestone® Boats and Boca Bay Boats – recently announced a new flagship model for Aquasport, a new website for the Aquasport brand, and delivery of the first Limestone® production boat. The Aquasport 3000CC center console is their largest model to date, becoming the latest flagship. It will make its official debut this summer and be available for order with shipments commencing this fall. “The new model showcases a flared bow and deep freeboard that Aquasport’s saltwater models are known for, all on a beautifully-running hull for an incredible ride and performance,” said Limestone CEO Scott Hanson. “Being stable, dry, and sure-footed in just about any chop, this model still...

Kirkland, Washington & Parsippany, New Jersey, Aug. 05, 2021 (GLOBE NEWSWIRE) — Pivotal Commware, Inc., a global leader in 5G mmWave smart infrastructure products, and CommAgility, a Wireless Telecom Group (NYSE American: WTT) brand and award-winning software supplier to 4G and 5G networks, today announced the integration of CommAgility’s physical layer software into Pivotal’s Echo 5G™ and Pivot 5G™ repeaters designed for delivering superior broadband experiences to more 5G mmWave subscribers at less cost. Echo is a low-profile, glass-attached repeater installed by subscribers to facilitate in-building penetration of mmWave signals from 5G small cells. The Pivot outdoor network repeater extends mmWave signals beyond the base station’s line-of-sight so carriers can increase coverage for less cost. Other members of Pivotal’s...

Novel iNKT agonist leads to a broad reprogramming of the innate and adaptive immune system to target cancer PORT-2 has the potential to re-sensitize checkpoint-resistant tumors to treatment with PD-1 antibodiesWESTPORT, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) — Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that the first patient has been dosed in the Oxford-led IMP-MEL study, a Phase 1/2, open-label, dose-escalation and randomized expansion clinical trial assessing the safety, tolerability and efficacy of PORT-2, a liposome formulation of the invariant natural killer T-cell (iNKT) agonist IMM60 developed for the treatment of solid tumors. Preclinical data for PORT-2 demonstrated...

Conference Call on Thursday, August 12th, 2021 at 3:00pm EST / 12:00pm PST San Francisco, CA, Aug. 05, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its second quarter 2021 financial results on Thursday, August 12th, 2021 at 3:00pm EST / 12:00pm PST. The second quarter 2021 financial results press release will be issued premarket the morning of Thursday, August 12th, 2021. Teleconference Date/Time Thursday, August 12th, 2021 at 3:00pm EST / 12:00pm PST Teleconference and Webcast Information To participate, please call 1 (877) 317-6789...

GREENWICH, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) — Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCM) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) today announced the following net asset value (“NAV”) estimate as of July 31, 2021.Management’s unaudited estimate of the range of the NAV per share of our common stock as of July 31, 2021 is between $6.68 and $6.78. This estimate is not a comprehensive statement of our financial condition or results for the month ended July 31, 2021. This estimate did not undergo the Company’s typical quarter-end financial closing procedures and was not approved by the Company’s board of directors. We advise you that our NAV per share for the quarter ending September 30, 2021 may differ materially from this estimate, which is given only as of July 31, 2021.As of July 31, 2021, the Company had approximately...

WILMETTE, Ill., Aug. 05, 2021 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced it has successfully reached its target of 20 activated clinical trial sites in the Phase 2b portion of the VOICE trial. Validive® is a small, easy-to-use mucobuccal tablet that can be self-administered in the patient’s home setting. The VOICE study evaluates Validive® for the prevention of severe oral mucositis (SOM) in oropharyngeal cancer patients. SOM results from the chemoradiation used to treat oropharyngeal cancer (OPC). There is no FDA-approved preventative or treatment option for the estimated >40,000 OPC patients in the US annually who are at-risk...